4 Biotech Stocks Wall Street Analysts Predict Will Gain More Than 60%

A $31.48 million consensus revenue estimate for the current quarter, ending June 30,  represents a 17.3% rise from the prior-year period. The stock has rallied 6.4% over the past year to close yesterday’s trading session at $5.86.

Wall Street analysts expect the stock to hit $9.50 in the near term, which indicates a potential 62.1% upside.

Agenus Inc.

AGEN is a clinical-stage immuno-oncology company that develops and commercializes technologies to treat cancers and infectious diseases. The company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies.

On May 18,  AGEN and Bristol-Myers Squibb Company (BMY)  agreed that BMY will be granted a global exclusive license to AGEN’s proprietary bispecific antibody program, AGEN1777. Because  BMY will be solely responsible for AGEN1777’s and other products’ commercialization, AGEN will receive a $200 million upfront payment and $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales.

As of March 31, the company had cash and cash equivalents of $119.37 million. Its cash used in operations for the fiscal 2021 first quarter ended March 31 was $42.74 million, compared to $35 million for the first quarter, ended March 31, 2020.

For the next quarter, ending September 30, analysts expect AGEN’s revenue to be $15.93 million, which represents a 13.8% rise from the prior-year period. The stock has gained 67.2% over the past year and 56.3% over the past month to close yesterday’s trading session at $4.18. It has gained 71.3% since hitting its 52-week low of $2.44.

Wall Street analysts expect the stock to hit $7.50 in the near term, which indicates a 79.4% potential upside. Also, all three Wall Street analysts covering the stock have rated it ‘Buy.’

VBI Vaccines Inc.

VBIV is a biopharmaceutical company that develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company develops  vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It serves primarily physicians and pharmacists through direct sales.

VBIV and Coalition for Epidemic Preparedness Innovations (CEPI) have partnered in March to develop VBIV’s enveloped virus like particle (eVLP) vaccine candidates against SARS-CoV-2 variants. CEPI will provide up to $33 million to support the advancement of VBI-2905 through Phase 1 clinical development. This funding will also support preclinical expansion of additional multivalent vaccine candidates designed to evaluate the potential breadth of VBIV’s eVLP technology.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.